Ofev 150 mg (Nintedanib) 60 capsules

Ofev 150 mg (Nintedanib)

Overview

Ofev 150 mg (active ingredient: Nintedanib) is an anti-fibrotic and tyrosine kinase inhibitor used to treat chronic, progressive lung diseases associated with fibrosis.
Manufactured by Boehringer Ingelheim, Ofev helps slow down the progression of scarring (fibrosis) in lung tissue and preserve lung function in patients with certain interstitial lung diseases.

Each capsule contains 150 mg of Nintedanib (as Nintedanib esilate).

Indications

Ofev 150 mg is prescribed for the treatment of:

• Idiopathic Pulmonary Fibrosis (IPF) — a chronic, progressive lung disease of unknown cause.
• Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).

These conditions are characterized by progressive lung scarring, leading to shortness of breath and reduced lung capacity.

Mechanism of Action

Nintedanib is a multi-target tyrosine kinase inhibitor that blocks signaling pathways involved in the development of lung fibrosis.
It inhibits receptors for:

• Vascular Endothelial Growth Factor (VEGF)
• Fibroblast Growth Factor (FGF)
• Platelet-Derived Growth Factor (PDGF)

By blocking these pathways, Ofev reduces fibroblast activity, slows tissue scarring, and helps preserve lung function.

Dosage and Administration

• Recommended dose: 150 mg twice daily (approximately every 12 hours).
• Capsules should be taken with food, swallowed whole with water — do not chew or open.
• In case of side effects or intolerance, the dose may be reduced to 100 mg twice daily, as directed by a physician.
• If a dose is missed, skip it and take the next one at the regular time — do not double dose.

All treatment must be initiated and monitored by a physician experienced in managing interstitial lung diseases.

Contraindications

Ofev 150 mg should not be used in patients with:

• Known hypersensitivity to Nintedanib or any of its components.
• Severe hepatic impairment (Child-Pugh Class B or C).
• Pregnancy or breastfeeding, unless specifically prescribed and monitored.

Use with caution in patients with:

• Bleeding disorders
• Cardiovascular disease
• Renal impairment

Adverse Reactions

Most common side effects:

• Diarrhea
• Nausea, vomiting
• Loss of appetite, weight loss
• Abdominal discomfort
• Elevated liver enzymes (ALT, AST)

Less common but serious reactions:

• Gastrointestinal perforation
• Severe hepatic injury
• Arterial thromboembolic events
• Proteinuria (protein in urine)
• QT prolongation

Regular monitoring of liver function tests (LFTs) and overall health is strongly recommended.

Manufacturer

Boehringer Ingelheim International GmbH
Ingelheim am Rhein, Germany